These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8625328)

  • 1. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.
    Alati T; Worzalla JF; Shih C; Bewley JR; Lewis S; Moran RG; Grindey GB
    Cancer Res; 1996 May; 56(10):2331-5. PubMed ID: 8625328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
    Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR
    Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.
    Synold TW; Newman EM; Carroll M; Muggia FM; Groshen S; Johnson K; Doroshow JH
    Clin Cancer Res; 1998 Oct; 4(10):2349-55. PubMed ID: 9796964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet.
    Habeck LL; Chay SH; Pohland RC; Worzalla JF; Shih C; Mendelsohn LG
    Cancer Chemother Pharmacol; 1998; 41(3):201-9. PubMed ID: 9443636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
    Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
    Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol.
    Mendelsohn LG; Gates SB; Habeck LL; Shackelford KA; Worzalla J; Shih C; Grindey GB
    Adv Enzyme Regul; 1996; 36():365-81. PubMed ID: 8869756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
    Worzalla JF; Shih C; Schultz RM
    Anticancer Res; 1998; 18(5A):3235-9. PubMed ID: 9858888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
    Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
    Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity.
    Schmitz JC; Grindey GB; Schultz RM; Priest DG
    Biochem Pharmacol; 1994 Jul; 48(2):319-25. PubMed ID: 8053927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
    Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
    Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.
    Leamon CP; Reddy JA; Dorton R; Bloomfield A; Emsweller K; Parker N; Westrick E
    J Pharmacol Exp Ther; 2008 Dec; 327(3):918-25. PubMed ID: 18791065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
    Zhao R; Gao F; Babani S; Goldman ID
    Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
    Reddy JA; Dorton R; Westrick E; Dawson A; Smith T; Xu LC; Vetzel M; Kleindl P; Vlahov IR; Leamon CP
    Cancer Res; 2007 May; 67(9):4434-42. PubMed ID: 17483358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
    Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG
    J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diet modulates the toxicity of cancer chemotherapy in rats.
    Branda RF; Chen Z; Brooks EM; Naud SJ; Trainer TD; McCormack JJ
    J Lab Clin Med; 2002 Nov; 140(5):358-68. PubMed ID: 12434138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
    Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
    Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
    Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.